Key result
Cardiac myosin activators, such as CK-1827452, improve cardiac performance by increasing systolic ejection time without altering intracellular calcium, offering a novel approach for heart failure.
Cardiac myosin activators represent a novel therapeutic approach for heart failure that improves cardiac performance by directly targeting the myosin head without the adverse effects of traditional inotropes.
No takes yet. Share an insight, caveat, or question.
May enable safer inotropy in heart failure; leaves open outcome benefits in clinical trials.
John R. Teerlink (2009) conducted a review in Heart failure. Cardiac myosin activators (CK-1827452) was evaluated. Cardiac myosin activators, such as CK-1827452, improve cardiac performance by increasing systolic ejection time without altering intracellular calcium, offering a novel approach for heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: